🇺🇸 FDA

Intelligence · Clinical Pipeline

Autoimmune & immunology · Phase II

Autoimmune & immunology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
327

Quick answer

Autoimmune & immunology Phase II programs: NovaPharmaNews indexes 327 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 6 of 7

  1. Roflumilast

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  2. Roflumilast Cream 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  3. Roflumilast foam 0.3%

    Arcutis Biotherapeutics

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  4. SAR441566

    Sanofi Pasteur

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  5. SAR442970, NANOBODY® Placebo

    Sanofi-aventis Healthcare Pty Ltd

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  6. SAR443122

    Sanofi Pasteur

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  7. SCD-044 Tablets 0.3mg, SCD-044 Tablets 0.6mg, SCD-044 Tablets 1.0mg, SCD-044 Tablets 0.1mg, placebo to match SCD-044 tablets

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  8. SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine

    Takeda

    Colitis, Ulcerative

    phase 2 small molecule completed

    1 trial

  9. SPY001

    Spyre Therapeutics

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  10. SPY002-072

    Spyre Therapeutics

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  11. SPYPBO-101 Placebo to SPY072, SPY072

    Spyre Therapeutics

    Moderately to Severely Active Rheumatologic Disease

    phase 2 small molecule active

    1 trial

  12. SPYPBO-102, SPYPBO-101, SPY002, SPY002, SPY001-001, SPY001-001

    Spyre Therapeutics

    Moderately to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  13. Sargramostim

    Hospital Authority, Hong Kong

    Pulmonary Alveolar Proteinosis, Autoimmune

    phase 2 small molecule completed

    1 trial

  14. Sarilumab

    Regeneron UK Limited

    Juvenile Idiopathic Arthritis

    phase 2 small molecule completed

    1 trial

  15. Sarilumab SAR153191 (REGN88)

    Regeneron UK Limited

    Juvenile Idiopathic Arthritis

    phase 2 small molecule active

    1 trial

  16. Sodium Chloride Intravenous Infusion (0.9% w/v), BP, Benlysta 400 mg powder for concentrate for solution for infusion.

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  17. Sonelokimab

    MoonLake Immunotherapeutics

    axial spondyloarthritis

    phase 2 small molecule active

    1 trial

  18. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    phase 2 small molecule active

    1 trial

  19. Splinting

    United Therapeutics Europe Ltd

    Hand Osteoarthritis

    phase 2 other completed

    1 trial

  20. Stem cells

    Takeda

    Rheumatoid Arthritis Aggravated

    phase 2 gene therapy completed

    1 trial

  21. Stromal-vascular fraction

    Century Therapeutics

    Knee Osteoarthritis

    phase 2 mab active

    1 trial

  22. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  23. TAK-018

    Takeda

    Crohn Disease

    phase 2 small molecule terminated

    1 trial

  24. TAK-079

    Takeda

    Myasthenia Gravis

    phase 2 small molecule completed

    1 trial

  25. TAK-279

    Takeda

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  26. TAK-279

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  27. TAK-279 Placebo (same excipient as TAK-279), ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  28. TAK-279 placebo (same excipient as TAK-279), ZASOCITINIB, ZASOCITINIB

    Takeda

    Moderately to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  29. TAK-715 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  30. TAK-783 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  31. TEV-48574

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  32. TEV-48574

    Teva Pharma GmbH

    Crohn Disease

    phase 2 small molecule completed

    1 trial

  33. TEV-48574 Dose Regimen A

    Teva Pharma GmbH

    Crohn Disease

    phase 2 small molecule active

    1 trial

  34. TEV-48574, Placebo IMP for sc infusion is provided as a liquid solution in the same formulation as TEV-48574, except for the absence of active protein.

    Lacuna Pharma Pty Ltd

    Crohn’s disease, Ulcerative colitis

    phase 2 small molecule active

    1 trial

  35. TOCILIZUMAB , CYCLOPHOSPHAMIDE , CD19-CAR_Lenti, FLUDARABINE , LEVETIRACETAM

    Fondazione Telethon ETS

    Refractory Systemic Autoimmune Diseases

    phase 2 small molecule active

    1 trial

  36. TV-45070

    Teva Pharma GmbH

    Osteoarthritis of the Knee

    phase 2 small molecule completed

    1 trial

  37. Taodan Granules

    Universal Integrated

    Psoriasis Vulgaris

    phase 2 small molecule active

    1 trial

  38. Teduglutide (ALX-0600)

    Takeda

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  39. Telitacicept

    The First People's Hospital of Lianyungang

    Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  40. Telotristat Etiprate

    LEXICON PHARMACEUTICALS, INC.

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  41. Tocilizumab Injectable Product

    Tang-Du Hospital

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  42. Topical Rose Bengal, 0.005%

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Psoriasis

    phase 2 small molecule completed

    1 trial

  43. Triamcinolone Acetonide Acetate and Urea Cream.

    Universal Integrated

    Psoriasis Vulgaris

    phase 2 small molecule active

    1 trial

  44. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  45. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  46. Ublituximab

    TG THERAPEUTICS, INC.

    Autoimmune Disorders

    phase 2 small molecule active

    1 trial

  47. Ultomiris 300 mg/30 mL concentrate for solution for infusion, Concentrate for solution for infusion

    Alexion Europe SAS

    Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

    phase 2 small molecule active

    1 trial

  48. Upadacitinib, Upadacitinib

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology Phase II programs exist?

327 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.